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Emerging evidence provides a scientific rationale
for combining treatment programs for neglected
tropical diseases (NTDs) with programs for the
treatment of HIV/AIDS. Engaging the major
stakeholders to establish operational links between
HIV/AIDS and NTD control and elimination
activities, especially in sub-Saharan Africa, could
increase the efficiency and cost-effectiveness of both
HIV/AIDS and NTD efforts.
NTDs in Sub-Saharan Africa
Sub-Saharan Africa is home to more
than 90% of the world’s cases of oncho-
cerciasis and schistosomiasis, about one-
half the world’s lymphatic filariasis and
trachoma, and one-third of all global soil-
transmitted helminth infections [1]. These
infections exhibit extensive geographic
overlap and polyparasitism in Africa is
extremely common [1–3]. The neglected
tropical diseases (NTDs) produce a devas-
tating level of chronic disability in sub-
Saharan Africa, with some estimates
suggesting that the NTD disease burden
exceeds tuberculosis and is one-half that of
malaria [1]. Most of the African popula-
tion living in poverty is infected with one
or more NTDs [1]. In children, the NTDs
are responsible for anemia and other
forms of malnutrition, intestinal obstruc-
tion, and impaired physical and cognitive
development [2–4]. In adults, NTDs cause
anemia, especially in pregnancy, damage
to internal organs, and physical disfigure-
ment [2–4]. The NTDs are among the
most common infections affecting the
health and well-being of girls and women
[5]. Through their impact on child develo-
pment, pregnancy outcome, and worker
productivity, the NTDs also thwart eco-
nomic development [6].
Because of the availability of donated or
generically available inexpensive drugs, it
is possible through the mass drug admin-
istration (MDA) of ‘‘rapid impact’’ pack-
ages containing albendazole/mebendazole,
ivermectin, praziquantel, and azithromycin
to reduce the prevalence, and in some cases
either control or eliminate these NTDs,
for as little as US$0.50 per person annually
[6]. MDA for the soil-transmitted hel-
minth infections and schistosomiasis, Afri-
ca’s highest prevalence NTDs, has been
priced at US$0.32 per person annually [7].
As a result of these low-cost and highly
cost-efficient opportunities for what is
sometimes referred to as preventive chemother-
apy, the United States Agency for Interna-
tional Development (USAID) is supporting
national programs of control or elimina-
tion of the most common NTDs in mul-
tiple African countries [8], with additional
country-wide programs expected to be
announced in the coming year. Addi-
tional national programs for scale-up of
NTD control are being supported by the
British Department for International De-
velopment (DFID) [9], while the Global
Network for Neglected Tropical Diseases is
mobilizing private resources for Rwanda
and Burundi, as well as other countries
[3,6].
HIV/AIDS and NTD Co-
Infections
HIV/AIDS and NTD co-infections are
widespread in sub-Saharan Africa, and
there is evidence that the high prevalence
helminth infections, i.e., the three major
soil-transmitted helminth infections (asca-
riasis, hookworm, trichuriasis), and schis-
tosomiasis either promote susceptibility to
the HIV virus or worsen the clinical course
and progression of AIDS, while visceral
leishmaniasis (VL) has emerged as an im-
portant opportunistic infection of HIV/
AIDS.
Visceral Leishmaniasis and HIV
The relationship between HIV/AIDS
and NTDs has been noted since the early
1990s. The World Health Organization
has recognized that VL can present as an
aggressive opportunistic infection in peo-
ple living with HIV/AIDS (PLWHA). If
left untreated, VL alone will cause mor-
tality rates as high as 100% within two
years [10]. In co-infected individuals, VL
and HIV mutually influence one another’s
disease progression, causing unrestrained
pathogen reproduction and profound im-
munosuppression, and higher VL treat-
ment failures and relapses [10]. Because
VL and HIV co-infections occur predom-
inantly in remote rural areas of East
Africa, there is little available data on the
prevalence of this problem [11]. However,
in northwest Ethiopia, up to 30% of all VL
patients are believed to be co-infected with
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tions between other NTDs, such as Chagas
disease, may occur in patients with HIV/
AIDS [12].
Helminth Infections and HIV
The geographic overlap between the high
prevalence helminth infections and HIV/
AIDS in sub-Saharan Africa is extensive.
More than 100 million people in sub-
Saharan Africa are infected with ascariasis,
hookworm, trichuriasis, or some combina-
tion of these soil-transmitted helminth
infections [1]; additional estimates suggest
that more than 400 million people suffer
from schistosomiasis [13]. The geographic
overlap is particularly striking between
urogenital schistosomiasis (Schistosoma haema-
tobium infection) and HIV/AIDS in the large
southern and East African countries of
Kenya, Mozambique, South Africa, Tanza-
nia, Zambia, and Zimbabwe, and to some
e x t e n t ,C a m e r o o ni nW e s tA f r i c a[ 7 , 1 4 ] .
These high prevalence helminth infec-
tions have an adverse, albeit largely hidden,
impact on the AIDS epidemic in Africa
[2,14–21]. While there are conflicting data
on this front [22–24], a systematic reviewof
randomized clinical trials demonstrates the
beneficial effects of deworming in terms of
reduced HIV viral loads and/or elevations
in CD4 counts [25]. Still further evidence
suggests that maternal helminth infections
promote maternal-to-child transmission of
HIV/AIDS, possibly as a result of in-
creased maternal HIV viral loads [26].
These effects were summarized recently
[14]. As a plausible mechanism, one uni-
fying hypothesis suggests that helminth
infections are immunomodulatory, possibly
diminishing host innate immunity to HIV
to promote viral replication and T cell
diminution [2,15–21]. Equally compelling
are data from Zimbabwe that female
genital schistosomiasis (FGS), occurring in
up to 75% of women with S. haematobium
infection, increases the risk of humans
acquiring HIV infection 3-fold [27]. Stud-
ies are underway elsewhere in southern and
East Africa to confirm these results. There
is also evidence that acute schistosomiasis
from Schistosoma mansoni infection increases
the risk of new HIV acquisition in rhesus
macaques [28]. These studies, together
with the observation that most of the
poorest people who live in sub-Saharan
Africa below the World Bank poverty level
are infected with schistosomes or some
other helminths [1,13], suggest that hel-
minth infections may represent a potent
force fueling Africa’s AIDS epidemic [29].
Therefore, early intervention to prevent
FGS through MDA with praziquantel for
young girls may represent a highly cost-
effective HIV/AIDS prevention strategy
[4,5,7] (Figure 1).
Linking Existing HIV Initiatives
with NTD Control
The high prevalence of helminth infec-
tions and other NTDs in sub-Saharan
Africa and their medical significance in
terms of affecting Africa’s AIDS epidemic
demand a public health response from the
established global HIV/AIDS community,
in parallel with efforts to scale up NTD
control. At the recent United Nations
2010 Millennium Development Goals
Summit, US President Barack Obama
announced a new approach to the pro-
grams that make up the United States
government’s Global Health Initiative. At
the core of this new directive is a call for
the integration of programs and invest-
ments across health priorities [30].
We support the US President’s call
for integration and would favor strategic
planning to examine how the US Presi-
dent’s Emergency Plan for AIDS Relief
(PEPFAR) and the Global Fund to Fight
AIDS, Tuberculosis and Malaria (GFA
TM), the two largest global programs
committed to delivering anti-retroviral
drugs and other AIDS prevention mea-
sures, could advance efforts to coordinate
and link the HIV/AIDS programs they
support with NTD control and elimination
programs [14]. Additional links with pro-
grams for malaria and tuberculosis control
have also been proposed [2,14].
As noted above, national programs of
NTD control and elimination are under-
way in more than a dozen sub-Saharan
Africa countries, with additional programs
expected in the coming years. These NTD
preventive chemotherapy programs deliv-
er partial or complete rapid impact pac-
kages, together with environmental con-
trol measures or simple surgeries, under
the auspices of public–private partnerships
working with national health ministries
[3,4,6]. NTD control and elimination is
conducted through a variety of mecha-
nisms, including community-based drug
distribution and school-based drug distri-
bution by teachers or through child health
days [3,4,6].
Currently, both PEPFAR- and GFATM-
supported programs provide treatment for
deadly tuberculosis co-infections in PLWHA
[31], as well as co-trimoxazole treatment to
prevent opportunistic infections. They also
provide nutritional support for PLWHA.
We propose that PEPFAR- and GFATM-
supported programs could also work with
USAID’s Neglected Tropical Disease Pro-
gram and similar initiatives supported by
DFID and the Global Network for NTDs
to mitigate the impact of NTD-related
morbidity on their target populations [14].
Such NTD control programs could contin-
ue to operate autonomously, but coordi-
nate the scale-up of MDA interventions in
areas found to bear high prevalence rates
of NTDs and HIV/AIDS. In addition to
scaling up MDA efforts, PEPFAR- and
GFATM-assisted programs could engage
Figure 1. Schematic diagram highlighting the bi-directionality of the pathogenic links
between NTDs and HIV/AIDS.
doi:10.1371/journal.pntd.0001022.g001
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evidence that NTD control could both de-
crease susceptibility to HIV infection and
improve morbidity levels in seropositive
individuals. Here, we use some of the pro-
grams of PEPFAR as examples to illustrate
how NTDs might fit into an existing
framework for the care and treatment of
HIV/AIDS (Figure 2).
Treatment of NTD Co-Infections
In terms of providing treatment, there
are several areas within PEPFAR’s pro-
gramming that could link with NTD
control efforts. Just as PEPFAR programs
provide treatment options for tuberculosis
co-infections and chemoprophylaxis to pre-
vent other opportunistic infections, NTD
co-infections for PLWHA that receive
treatment through PEPFAR clinics could
also be addressed. These facilities could
be stocked with appropriate NTD medica-
tions based on regional NTD prevalence.
This approach would allow PLWHA to
be treated at the point of service, thus
minimizing the impact of NTDs on viral
replication. In addition, because many in-
dividuals who live in NTD-endemic areas
are unaware of their HIV status, NTD
control and elimination campaigns could
be expanded to provide HIV testing and
care. In this way there could be mutual and
bi-directional benefit.
PEPFAR antenatal clinics could actively
engage in NTD control as well. Up to one-
third of pregnant women in sub-Saharan
Africa are infected with hookworms [32],
while large numbers of pregnant women
are likely infected with schistosomiasis
[33], and suffer from severe anemia as a
result [1,32,33]. All pregnant mothers
visiting PEPFAR antenatal clinics in their
second or third trimesters could receive
single doses of albendazole and praziquan-
tel to prevent morbidity caused by soil-
transmitted helminth or schistosome in-
fections, respectively. Given that schisto-
some infection in young girls may cause
FGS in childhood prior to sexual debut
[7,27], thus increasing susceptibility to
HIV infection, PEPFAR could cooperate
with existing NTD control programs to
expand its targeted prevention efforts for
women beyond just antenatal clinics,
especially for the targeted treatment of
FGS.
Care
PEPFAR’s care initiatives have two
entry points for NTD control, both of
which would decrease morbidity in PL
WHA by building upon existing program-
ming. PEPFAR community health care
workers (CHWs) visit the homes of or-
phans and vulnerable children (OVC)
infected and affected by HIV/AIDS to
monitor growth and development. These
health care workers can be trained to
administer the appropriate NTD chemo-
prophylaxis based on prevalence mapping.
Many OVCs, who are often missed by
school-based deworming programs, would
benefit. Similar to the OVC program,
PEPFAR sends CHWs to the homes of
PLWHA that are unable to travel to local
clinics. PEPFAR could integrate NTD
control into both the OVC and home-
based care programs to respond to the risk
of chronic immune activation in co-
infected individuals.
Research
Operational research to evaluate the
successes and failures for HIV/AIDS and
NTD control are critical, as is research
and development for new and improved
control tools for the NTDs [34].
Integration in Action
Integrating NTD control into a PEP-
FAR or GFATM framework would re-
quire careful coordination and collabora-
tion with the USAID’s NTD Program, as
well as with parallel efforts supported by
DFID and the Global Network for NTDs,
and most importantly the health ministries
in the disease-endemic countries together
with public–private partnerships commit-
ted to NTD control. Embracing the
control of the NTDs, the most common
infections of girls and women in develop-
ing countries [5], is also consistent with
recent calls to expand PEPFAR’s mandate
to include maternal and child health
initiatives [35]. In the meantime, there is
a need for studies to confirm the cost-
effectiveness of linking NTDs with HIV/
AIDS. Funding will need to be arranged
for the proposed scale-up of MDA by
USAID’s NTD Program and targeted
interventions, as carried out by PEPFAR
and GFATM. However, with the excep-
tion of praziquantel, most NTD drugs are
fully funded through existing public–pri-
vate partnerships with pharmaceutical
companies, meaning that the overall costs
will be relatively low, particularly as
compared to the cost of intervening for
malaria or tuberculosis [14].
Evidence speaking to the biological
relationship between NTDs and HIV/
AIDS means that effective management of
HIV/AIDS may require the control of
NTDs. The past successes in integrating
directly observed therapy for tuberculosis
[31], co-trimoxazole chemoprophylaxis,
and nutritional support into HIV/AIDS
programming indicates it is also possible to
incorporate NTD preventive chemothera-
py in HIV/AIDS treatment regimens. A
full consideration of NTD control will
require meaningful cooperation from the
public health community. Bilateral orga-
nizations will need to nurture systems of
collaboration within their existing opera-
tional frameworks. Multilateral and pri-
vate funding organizations will need to
Figure 2. Schematic diagram representing the operational links for integrated control
of NTDs and HIVS/AIDS.
doi:10.1371/journal.pntd.0001022.g002
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control and actively seek out organizations
prepared to implement new strategies.
Like any public health initiative requiring
a systems change on a global scale, change
has been slow to arrive. However, as the
consequences of decades of neglect accu-
mulate, and the AIDS pandemic itself
continues, it is more and more apparent
that the public health community can no
longer afford to disregard the importance
of aggressively controlling NTDs as part of
a strategy to address HIV infection.
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